In this randomized controlled trial, supplementation with beta-hydroxybutyrate improved inflammatory biomarkers and reduced the length of hospitalization in adults with COVID-19–related acute respiratory distress syndrome (ARDS).

Beta-hydroxybutyrate, an oral adjunct therapy, has shown promising results in ameliorating symptoms of ARDS. This includes reduced inflammation, oxidative stress, and decreased patient fatigue levels. Further study with a large sample size is warranted to assess the potential of BHB therapy’s effectiveness in reducing the development of severe illness.

In this 5-day randomized controlled trial, the participants took 50 grams of BHB (in two 25-gram doses) or a placebo (maltodextrin) daily. All of the participants were instructed to take their supplements with water before meals and follow a “standard diet”, which wasn’t specified.

Read More